Effects of Lactobacillus casei and Bifidobacterium breve on urinary oxalate excretion in nephrolithiasis patients.
It had been suggested that lactic acid bacteria (LAB) may degrade oxalate in the intestinal lumen, reducing urinary oxalate excretion. We aimed to evaluate the effect of a LAB mixture containing Lactobacillus casei (LC) and Bifidobacterium breve (BB) (LC + BB) upon urinary oxalate reduction in stone-forming (SF) patients without hyperoxaluria under conditions of an oxalate-rich diet. After an oxalate restriction period (7 days washout), 14 SF patients consumed an oxalate-rich diet during 4 weeks (200 mg/day) and a lyophilized LC + BB preparation was given t.i.d. after meals during the last 2 weeks. Twenty-four-hour urine samples were collected for determination of oxalate, calcium, magnesium, citrate, sodium, potassium and creatinine at baseline, after 2 weeks (DIET) and 4 weeks (DIET + LC + BB). The mean urinary oxalate excretion was significantly higher after DIET versus baseline (27 +/- 8 vs. 35 +/- 11 mg/24 h), but the mean decrease was not significant between DIET + LC + BB and DIET periods (35 +/- 11 vs. 33 +/- 10 mg/24 h). Seven out of 14 patients presented a reduction in oxaluria after LC + BB versus DIET, being the reduction higher than 25% in 4, and up to 50% in 2 of them. The latter two patients were those who had presented the greatest increase in oxaluria in response to dietary oxalate. In conclusion, this mixture of L. casei and B. breve was shown to possess a variable lowering effect upon urinary oxalate excretion that may be dependent on dietary oxalate intake.
Ferraz
Renato Ribeiro Nogueira
RR
Nephrology Division, Universidade Federal de São Paulo, UNIFESP, Rua: Botucatu, 740, Vila Clementino, 04023-900, São Paulo, SP, Brazil.
Marques
Natália Cristina
NC
Froeder
Leila
L
Menon
Viviane Barcellos
VB
Siliano
Priscila Reina
PR
Baxmann
Alessandra Calábria
AC
Heilberg
Ita Pfeferman
IP
D000328:Adult; D001644:Bifidobacterium / Q000378:metabolism; D004032:Diet; D005260:Female; D005504:Food Analysis; D006801:Humans; D007780:Lacticaseibacillus casei / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D053040:Nephrolithiasis / Q000382:microbiology / Q000628:therapy* / Q000652:urine*; D010070:Oxalates / Q000008:administration & dosage / Q000652:urine*; D019936:Probiotics / Q000627:therapeutic use*
D010070:Oxalates